Defibrotide does not interfere with the antileukemic and the anti-PBMC effects of F-Ara.

F-Ara, 10 μg/mL. D, 100 μg/mL. (A) PI staining of primary AML cells derived from a patient in blast crisis (70% blasts of total PBMC count). Results are given in mean percentage vitality of 3 independent experiments. *P = .008 of control versus F-Ara–treated AML cells. (B) Flow cytometric analysis of the SSC image of PI-negative PBMCs. Shown is 1 of 5 independent experiments with different blood donors.